Cas:232597-44-3 tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate manufacturer & supplier

Chemical Name:tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate

CAS.NO:232597-44-3

Synonyms:tert-butyl 4-(1-hydroxyethyl)phenylcarbamate;GL-0162;1-(4-BOC-Aminophenyl)ethanol

Molecular Formula:C₁₃H₁₉NO₃

Molecular Weight:237.29500

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:316.3ºC at 760mmHg

Density:1.132g/cm3

Index of Refraction:1.554

PSA:58.56000

Exact Mass:237.13600

LogP:3.15990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 4-(1-hydroxyethyl)phenylcarbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(4-BOC-Aminophenyl)ethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(4-BOC-Aminophenyl)ethanol Use and application,tert-butyl 4-(1-hydroxyethyl)phenylcarbamate technical grade,usp/ep/jp grade.

Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate manufacturer Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate supplier Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets. tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. tert-butyl N-[4-(1-hydroxyethyl)phenyl]carbamate factory Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.